Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Cell. Infect. Microbiol.

Sec. Antibiotic Resistance and New Antimicrobial drugs

Naringenin targets FimZ to regulate type I fimbriae and reduce the virulence of Salmonella

Provisionally accepted
  • 1The First Hospital of Jilin University, Changchun, China
  • 2Jilin Engineering Normal University, Changchun, China
  • 3Department of Gastroenterology, The First Hospital of Jilin University, Changchun, China

The final, formatted version of the article will be published soon.

Salmonella infection severely affects the healthy development of livestock and poultry, as well as food safety and public health. The critical role of type I fimbriae (TIFs) in promoting Salmonella pathogenicity makes them important targets for exploring inhibitors of Salmonella infection. In this study, we found that naringenin (Nar) inhibited the invasion of Salmonella into HeLa cells but did not affect bacterial motility. Nar reduced the transcription levels of the TIF structural proteins FimA and FimH and the chaperone proteins FimC and FimD, as determined via RT–qPCR. Molecular docking and surface plasmon resonance (SPR) assays confirmed that Nar was bound to FimZ, which directly regulates the expression of TIF, resulting in a reduction in TIF formation accompanied by a decrease in biofilm formation and bacterial adhesion to cells and alleviation of the inflammatory response. In vivo, Nar prolonged the survival of mice infected with Salmonella, improved the survival rate, reduced the inflammation level and bacterial load, and significantly alleviated histopathological damage. These results provide alternative strategies and promising lead compounds for controlling Salmonella infection.

Keywords: Type I fimbriae, Inflammation, Salmonella, FimZ, NAR

Received: 19 Jun 2025; Accepted: 28 Nov 2025.

Copyright: © 2025 Meng, Wang, Lu, Duan, Wen, Zhang, Hu and Rao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Min Rao

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.